modification has the potential to antagonize histone methylation and coordinate with histone deacetylation to regulate gene transcription.
Moreover, PADI4 can interact with tumor suppressor p53 to regulate its transcriptional activity. 12 We found that PADI4 can stimulate the proliferation, invasion, and migration of ovarian cancer cell line A2480 via p53 signaling. 13 We also found that PADI4 is a gastric carcinoma susceptibility gene and that it up-regulates the expression levels of CXCR2, KRT14, and TNF-α, which are well-known activators of angiogenesis, cell proliferation, cell migration, and the immune microenvironment in tumors. 14 An anti-cancer PAD inhibitor is being considered as a potential drug to treat tumors. 15 However, the above studies that investigated the tumorigenic role of PADI4 were completed in cultured tumor cell lines. No evidence that shows the effect of PADI4 on tumor development under in vivo conditions exists, and no studies have investigated the tumorigenic pathway of this enzyme in an animal model.
We previously detected significantly increased PADI4 transcription and translation in esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) tissues. Furthermore, we found that the PADI4 level is positively correlated with the pathological classification of ESCC. The PADI4 gene has been validated as an esophageal cancer (EC) susceptibility gene. 16 These results suggest that PADI4 expression is related to the tumorigenic process of EC. In the current study, we established tumor-bearing mice with ECA109 cells, which originate from ESCC, that were transfected with a PADI4-expressing lentivirus before injection. We aimed to determine the effect of PADI4 on tumor growth using the experimental animals. Our study also investigated the down-stream pathway of PADI4 in ECA109 cells using PCR arrays and then verified the results in EC using the animal tumors established with PADI4-overexpressing cells.
| MATERIALS AND METHODS

| Tissue collection
All solid tumor tissues and adjacent tissues used in this study were obtained from patient surgeries at Shandong Province Qianfoshan Hospital in Jinan, Shandong, P. R. China. Tumor diagnosis was carried via histological methods, and the pathological categorization was performed according to the World Health Organization (WHO) classification system.
| Antibodies
The primary antibodies used in this study were against the following 
| Quantitative real-time reverse transcription PCR (qRT-PCR)
Total RNA from cultured cells or ESCC tissues was extracted using the TRIzol reagent (Life Science, Carlsbad, CA). The extract was reversely transcribed into first-strand cDNA and used as the PCR template with the primers PADI4-Q forward (PADI4-QF) and PADI4-Q reverse (PADI4-QR) (Table S1 ). qRT-PCR was performed in a 10-µL mixture total volume, composed of 5 µL of SYBR Green Real-time PCR Master Mix (Toyobo, Osaka, Japan), 1 µL of cDNA (1:10 diluted), 1 µL of 1 µmol/L forward primer, 1 µL of 1 µmol/L reverse primer and 2 µL of ddH 2 O. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used for quantity and quality control. Data were analyzed using the following formula:
, where R is the relative expression level, ΔCt sample is the difference between the target gene Ct and the average GAPDH Ct in the sample, and ΔCt control is the difference between the target gene Ct and the average GAPDH Ct in the control sample.
The expression of ANGPT1, CA9, and TEK was also examined by qRT-PCR in ECA109 cells with PADI4 overexpression or knockdown.
The PCR primers designed for this study are shown in Supplementary Material Table S1 .
| Western blot analysis
ESCC tissues (n = 20) and their corresponding adjacent tissues (n = 20)
were excised during surgery. Sample tissues (100 μg) were homogenized in RIPA cell lysis solution (Solarbio, Beijing, China) and centrifuged at 12 000g for 15 min at 4°C. The supernatants were collected after centrifugation, and their protein concentrations were determined using a BCA protein assay kit (Beyotime Biotechnology, Shanghai, China). The total protein extract was separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a polyvinylidene fluoride (PVDF) membrane. Western blot analysis was conducted using the anti-PADI4 antibody (1:2000) . All primary and secondary antibodies were diluted in 5% nonfat dry skim milk in TBST (Tris buffered saline, pH 7.6) that contained 0.1% Tween 20.
Immunoreactive signals were detected with horseradish peroxidase (HRP)-conjugated secondary antibodies and visualized using Western blotting luminol reagent (Millipore, Bedford, MA). The blotting images were acquired with an Alpha FluorChem E (ProteinSimple, SantaClara, CA). A second PVDF membrane was prepared using the same protocol as that used with the primary blot, and this second membrane was hybridized with anti-GAPDH antibody to normalize sample loading.
The expression of ANGPT1, CA9 and TEK in ECA109 cells was measured using a similar protocol. The immunoreactive signals were visualized using immunofluorescent secondary antibodies, which stain the target protein red (Alexa 568 con-jugated) or green (Alexa 488 conjugated). To determine antibody specificity and to optimize the antibody dilutions, tissue samples were incubated with the modification buffer without antibody. 4', 6-diamidino-2-phenylindole (DAPI) was used to stain the cell nuclei.
| Immunohistochemistry
| Overexpression of PADI4 in ECA109 and EC9706 cells
The full PADI4 sequence used for overexpression was approximately 1992 bp, encoding 663 amino acid residues, and it was synthesized and sequenced by Genecreate (Wuhan, China). The full PADI4 sequence was then amplified via PCR using the following specific pair of primers: PADI4-EcoRI-Fex (forward) and PADI4-AscI-Rex (reverse). The PCR primers designed for this study are also shown in Supplementary Material Table S1 .
The PCR product was inserted into the pCDNA3. were gently mixed and incubated for 15 min at room temperature. Each DNA-lipid mixture was subsequently added to a well with 900 µL of RPMI 1640 complete culture medium (including 10% fetal calf serum, 100 U/mL penicillin and 100 mg/mL streptomycin) and incubated with serum for 16 h. The medium was then replaced with RPMI 1640 complete culture medium (including 10% fetal calf serum, 100 U/mL penicillin and 100 mg/mL streptomycin) and cultured for 48 h at 37°C with 5% CO 2 . The transfected cells were then harvested for further experiments.
| Inhibition of PADI4 expression with siRNA
A PADI4 siRNA oligonucleotide with the target sequence 5′-CAGCG TAGTCTTGGGTCCCAA-3′ was designed and synthesized by Qiagen (Hilden, Germany). The ECA109 and EC9706 esophageal cancer cell lines were cultured separately in six-well tissue culture plates with 2 mL of RPMI 1640 (Gibco, Auckland, New Zealand) complete culture medium (10% fetal calf serum, 100 U/mL penicillin, and 100 mg/mL streptomycin) at 37°C with 5% CO 2 until cell confluency reached 70-80%. HiPerFect transfection reagent (Qiagen) was used for siRNA transfection at a concentration of 20 nM according to the manufacturer's protocol. Transfected cells were harvested for further experiments after 48 h of transfection.
| Cell proliferation assay
The effect of PADI4 on ECA109 and EC9706 cell proliferation was evaluated using a Cell Counting Kit-8 (CCK-8, Dojindo, Kyushu, Japan).
The recombinant overexpression plasmid pCDNA3.1-PADI4-RFP was transfected into ECA109 and EC9706 cells separately using the PolyJet™ DNA in vitro transfection reagent, and the cells were cultured for 24 h.
PADI4-overexpressing ECA109 and EC9706 cells were separately seeded into 96-well culture plates (5000/well) for 24 h of culture at 37°C with 5% CO 2 . The blank pCDNA3.1-RFP plasmid was used as a non-specific control. After incubating for 24 h with the DNA-lipid mixture in complete culture medium, the PADI4-overexpressing ECA109 and EC9706 cell medium was replaced with complete RPMI 1640 (including 10% fetal calf serum, 100 U/mL penicillin, and 100 mg/mL streptomycin), and culturing was continued for an additional 36 h at 37°C with 5% CO 2 . Ten microliters of CCK-8 solution was then added to the cell culture medium in each well, and culturing was continued for another 2 h at 37°C with 5% CO 2 . Finally, the absorbance was measured at 450 nm with a spectrophotometer (Spectramax 190; Molecular Devices). Growth graphs were generated from the average values of five wells from each group. 
| PCR array analysis
| Statistics
Data were analyzed by two-tailed Student's t-tests. Differences were considered statistically significant at P < 0.05. To verify the results, each experiment was performed with three samples in triplicate.
3 | RESULTS
| Determining PADI4 expression in EC tissues
To We also conducted proliferation assays using CCK8 assays in both In summary, we identified the stimulatory effects of PADI4 on tumor development in an animal model. We found that increased PADI4 expression in ESCC up-regulates CA9 expression, which is known to promote tumorigenesis and metastatic properties. These important roles of PADI4 that were identified provide a new understanding of the ESCC tumorigenic process.
